Red Wine's Health Benefits May Be Due In Part To

December 17, 1997

CHICAGO --- Researchers at Northwestern University Medical School have found that a chemical in red wine believed to help reduce risk for heart disease is a form of estrogen. The substance, resveratrol, is highly concentrated in the skin of grapes and is abundant in red wine.

Moderate consumption of red wine has been widely reported to reduce risk for cardiovascular disease. Some researchers have attributed this cardioprotective quality to the significant amounts of resveratrol naturally present in grape skin.

Resveratrol protects grapes and some other plants against fungal infections. It has been shown previously to have a number of potentially beneficial properties, including antioxidant, anticoagulant, anti-inflammatory and anti-cancer effects.

Resveratrol has a molecular structure similar to that of diethylstilbestrol, a synthetic estrogen. This prompted Barry D. Gehm, J. Larry Jameson, M.D., and colleagues at Northwestern to investigate whether resveratrol might have pharmacologic properties similar to those of estradiol, the major natural human estrogen.

As reported in the Dec. 9 issue of the Proceedings of the National Academy of Sciences, the group's laboratory studies showed that resveratrol is estrogenic. (Specifically, it is a phytoestrogen, from the Greek word for "plant.") At concentrations similar to those required for its other biological effects, resveratrol activated expression of both artificially introduced "reporter" genes and naturally occurring estrogen-regulated genes in cultured human cells.

The researchers also found that resveratrol could replace estradiol in supporting the proliferation of certain breast cancer cells that require estrogen for growth.

"Estrogen" is not a specific compound but a category of substances defined by their biological effect. Originally named for their ability to induce estrus ("going into heat") in animals, estrogens act on cells by binding to a protein called estrogen receptor, which then causes certain genes to be expressed, or "turned on." In addition to the body's sex hormones, a number of other natural and artificial estrogens are known.

In studying gene expression, many laboratories use artificial reporter genes. The reporter gene used in these studies is the gene for the enzyme luciferase, which makes fireflies light up. It was connected to a piece of DNA that the estrogen receptor "recognizes." When this reporter gene was put into cells, luciferase production increased in those treated with estrogen. Then, when mixed with certain chemicals, the enzyme was measured easily by the light it gave off.

In some cells, resveratrol caused more expression of the reporter gene than estradiol. This was surprising, Gehm said, since estradiol has always been thought to produce maximal activation of the estrogen receptor. The group found that the most effective dose of resveratrol produced two to four times more light as the most effective dose of estradiol. However, estradiol is effective at much lower doses.

"The estrogenic properties of resveratrol may play a role in the beneficial cardiovascular effects of red wine and the so-called 'French paradox,'" Gehm said.

Estrogen is known to provide some protection against heart disease, and red wine also appears to. Their specific effects are similar, most notably, increasing high-density lipoprotein (HDL), the "good cholesterol." This effect of red wine may be mediated by resveratrol.

But Gehm cautioned that it is not yet known if the body absorbs enough resveratrol from wine to make this plausible. The same can be said of resveratrol's other effects, described earlier.

Some researchers have previously suggested that it would be beneficial to supplement people's diets with resveratrol because of its anticarcinogenic and anti-arteriosclerotic properties.

"The discovery that resveratrol is estrogenic means that such supplementation might have undesirable side effects," Gehm said.

Nevertheless, the observation that reseveratrol produces greater expression of some estrogen-regulated genes than estradiol may ultimately lead to the development of new, more selective estrogenic drugs. Selective estrogens currently available are used in the treatment of breast cancer (tamoxifen) and postmenopausal osteoporosis (raloxifene).

Barry D. Gehm is a research assistant professor of medicine; J. Larry Jameson, M.D., is the C. F. Kettering Professor of Medicine and chief of endocrinology at Northwestern University Medical School. Also collaborating on this study were Joanne M. McAndrews and Pei-Yu Chien.

Northwestern University

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to